PT PYRIDAM FARMA TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113 IDR | -4.24% |
|
-5.04% | -90.13% |
| 10/05 | Foreign Investment Review Board Clears Probiotec Acquisition by Pyridam Farma | MT |
| 15/03 | PT Pyridam Farma Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 72TCr 4.44Cr 366.37Cr | Sales 2023 | 70TCr 4.35Cr 359.53Cr | Capitalization | 61TCr 3.8Cr 313.75Cr |
|---|---|---|---|---|---|
| Net income 2022 | 28TCr 1.71Cr 141.07Cr | Net income 2023 | -8.52TCr -52.84L -44Cr | EV / Sales 2022 | 1.73 x |
| Net Debt 2022 | 77TCr 4.8Cr 396.09Cr | Net Debt 2023 | 90TCr 5.56Cr 459.36Cr | EV / Sales 2023 | 2.15 x |
| P/E ratio 2022 |
1.68
x | P/E ratio 2023 |
-7.19
x | Employees | 1,193 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.08% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.24% | ||
| 1 week | -5.04% | ||
| Current month | -4.24% | ||
| 1 month | +29.89% | ||
| 3 months | -85.96% | ||
| 6 months | -90.96% | ||
| Current year | -90.13% |
1 week
112.00
135.00
1 month
81.00135.00
Current year
81.001 545.00
1 year
81.001 545.00
3 years
81.001 545.00
5 years
81.001 640.00
10 years
81.001 640.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yan Gwan Lee
CEO | Chief Executive Officer | 61 | 14/20/14 |
Yenfrino Gunadi
DFI | Director of Finance/CFO | 38 | 14/20/14 |
Bedjo Stefanus
PRN | Corporate Officer/Principal | 60 | 22/23/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 25/15/25 | |
Robby Yulianto
CHM | Chairman | 42 | 14/20/14 |
| Director/Board Member | 65 | 10/22/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 113 | -4.24% | 85,046,300 |
| 31/24/31 | 118 | -7.09% | 82,261,000 |
| 30/24/30 | 127 | -3.79% | 85,601,400 |
| 29/24/29 | 132 | +6.45% | 136,051,200 |
| 28/24/28 | 124 | +4.20% | 75,644,400 |
End-of-day quote INDONESIA S.E., June 03, 2024
More quotes
PT Pyridam Farma Tbk is an Indonesia-based pharmaceutical company. The Company is engaged in the production, development, and trade of pharmaceuticals, as well as the trade of medical devices and cosmetics. Its segments include pharmaceutical products, esthetic, and toll manufacturing services; and medical equipments. It offers products across consumer health, pyfaesthetic, sanitizer and antiseptic, sterile/injection, biomedilab, betadine group and guardix, and medical support categories. The consumer health category provides over the counter drugs, including supplements and other preventive products, along with energy drinks and healthy ready-to-drink products. Its pyfaesthetic category includes products, such as Arosa Gel, A-Stark Gel, Hymen Gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb Gel. Its sterile/injection category is focused on injection products. Its biomedilab category provides various medical equipment and tools for hospital laboratories.
Sector
Pharmaceuticals
Calendar
23/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -90.13% | 8.16Cr | |
| +42.60% | 74TCr | |
| +32.34% | 60TCr | |
| -5.74% | 35TCr | |
| +17.79% | 32TCr | |
| +3.37% | 28TCr | |
| +16.47% | 24TCr | |
| +9.26% | 21TCr | |
| -5.07% | 21TCr | |
| +6.74% | 16TCr |
- Stock Market
- Equities
- PYFA Stock
